ASCO Annual Meeting: Best of Hematology | Conference

Julie Vose, MD, MBA, Discusses Novel Treatment Options for Hematologic Malignancies
July 29, 2021

Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center, discusses novel treatment options for patients with hematologic malignancies at the 2021 American Society of Clinical Oncology Annual Meeting.

Julie Vose, MD, MBA, on the Use of CAR T-Cell Therapy in Lymphomas
July 28, 2021

Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.

Julie Vose, MD, MBA, Discussed Toxicities Associated With Acalabrutinib or Ibrutinib for Chronic Lymphocytic Leukemia
July 27, 2021

CancerNetwork® sat down with Julie Vose, MD, MBA, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about a clinical trial comparing acalabrutinib versus ibrutinib for patients with chronic lymphocytic leukemia.

Shaji Kumar, MD, on Daratumumab Maintenance Following Transplant for Myeloma in CASSIOPEIA
July 11, 2021

At ASCO 2021, Shaji Kumar, MD, talked about the impact of adding daratumumab maintenance to therapy for patients with newly diagnosed multiple myeloma in the CASSIOPEIA trial.

Mounzer E. Agha, MD, Discussed the Value of ASCO Annual Meeting for Multiple Myeloma
July 05, 2021

Agha emphasized that the annual conference allows investigators to set the foundation for what’s to come in the treatment of multiple myeloma and other hematologic malignancies.

Philippe Moreau, MD, on Updates in Multiple Myeloma Presented at ASCO 2021
June 25, 2021

Moreau highlighted important updates in the field of multiple myeloma, including the CARTITUDE-1 trial, which yielded promising results with ciltacabtagene autoleucel and read out at the 2021 ASCO Annual Meeting.

Saad Z. Usmani, MD, MBA, FACP, on Intriguing Data for High-Risk Multiple Myeloma at 2021 ASCO
June 24, 2021

Usmani highlighted the FORTE study as one of the trials investigating the high-risk cohort of patients.

Ola Landgren, MD, PhD, on Data From CARTITUDE-2 at 2021 ASCO
June 10, 2021

Ola Landgren, MD, PhD, looks at results from the phase 2 CARTITUDE-2 trial of ciltacabtagene autoleucel for patients with multiple myeloma and 1 to 3 prior lines of therapy presented at the 2021 ASCO Annual Meeting.

Paul M. Barr, MD, Examines Head-to-Head Data on BTK Inhibitors in Previously Treated, High-Risk CLL
June 09, 2021

CancerNetwork® sat down with Paul M. Barr, MD, at the 2021 ASCO Annual Meeting to talk about what data has the greatest potential to impact standard treatment of chronic lymphocytic leukemia.